- Previous Close
25,450.00 - Open
24,900.00 - Bid 25,400.00 x --
- Ask 25,450.00 x --
- Day's Range
24,900.00 - 25,750.00 - 52 Week Range
24,250.00 - 52,500.00 - Volume
64,943 - Avg. Volume
101,314 - Market Cap (intraday)
1.744T - Beta (5Y Monthly) 0.96
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date May 1, 2025 - May 5, 2025
- Forward Dividend & Yield 300.00 (1.17%)
- Ex-Dividend Date Dec 27, 2024
- 1y Target Est
--
Hanmi Science Co., Ltd., through its subsidiaries, manufactures and sells pharmaceutical products in Korea and internationally. It develops drugs in the areas of diabetes and anti-cancer, as well as children's and adult's bowel preparation and cold medicines, and cephalosporin antibiotics. The company also offers general foods, health functional foods, soy milk, and medical equipment. In addition, it offers automated drug management systems. The company sells its products through online and offline pharmacies. The company was formerly known as Hanmi Holdings Co., Ltd. and changed its name to Hanmi Science Co., Ltd. in March 2012. Hanmi Science Co., Ltd. was founded in 1973 and is headquartered in Seoul, South Korea.
www.hanmiscience.co.krRecent News: 008930.KS
View MorePerformance Overview: 008930.KS
Trailing total returns as of 4/4/2025, which may include dividends or other distributions. Benchmark is KOSPI Composite Index (^KS11) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 008930.KS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 008930.KS
View MoreValuation Measures
Market Cap
1.74T
Enterprise Value
1.87T
Trailing P/E
29.33
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.36
Price/Book (mrq)
2.07
Enterprise Value/Revenue
1.46
Enterprise Value/EBITDA
22.24
Financial Highlights
Profitability and Income Statement
Profit Margin
4.63%
Return on Assets (ttm)
1.84%
Return on Equity (ttm)
6.89%
Revenue (ttm)
1.28T
Net Income Avi to Common (ttm)
59.42B
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
89.25B
Total Debt/Equity (mrq)
25.62%
Levered Free Cash Flow (ttm)
74.2B